Weeks af­ter clos­ing Bris­tol My­ers deal, Karuna's ex-CEO heads to Black­stone-backed An­thos

How does Bill Meury cel­e­brate a $14 bil­lion merg­er? With a new post at a Black­stone-found­ed biotech.

Meury has been ap­point­ed CEO at An­thos Ther­a­peu­tics, just over a month af­ter clos­ing Karuna Ther­a­peu­tics’ sale to Bris­tol My­ers Squibb. He pre­vi­ous­ly held se­nior roles at Al­ler­gan and Ac­tavis.

An­thos, which spun out of No­var­tis in 2019, is de­vel­op­ing a next-gen­er­a­tion blood thin­ner de­signed to pre­vent strokes and clots, but with low­er risk of bleed­ing than cur­rent ther­a­pies. Re­cent Phase 2 re­sults sug­gest a 150 mg dose of the can­di­date, abelacimab, re­duced the risk of bleed­ing by 67% com­pared to Bay­er and John­son & John­son’s block­buster Xarel­to in pa­tients with atri­al fib­ril­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER